S
Stephen R. Saklad
Researcher at University of Texas at Austin
Publications - 43
Citations - 1549
Stephen R. Saklad is an academic researcher from University of Texas at Austin. The author has contributed to research in topics: Haloperidol & Medicine. The author has an hindex of 18, co-authored 36 publications receiving 1375 citations. Previous affiliations of Stephen R. Saklad include Texas Department of State Health Services & University of Texas Health Science Center at San Antonio.
Papers
More filters
Journal ArticleDOI
Abuse and Misuse of Pregabalin and Gabapentin.
TL;DR: Evidence suggests gabapentinoids possess potential for abuse, particularly in individuals with a history of opioid abuse, and reports of such abuse are increasingly being documented, and prescribers should be aware of high-risk populations and monitor for signs of abuse.
Journal ArticleDOI
Effects of smoking on haloperidol and reduced haloperidol plasma concentrations and haloperidol clearance
Michael W. Jann,Stephen R. Saklad,Larry Ereshefsky,Ann L. Richards,Charles A. Harrington,Chester M. Davis +5 more
TL;DR: Plasma concentrations of haloperidol and its reduced metabolite (reduced haloperIDol) were investigated in cigarette smokers and nonsmokers and did not show significant differences between smokers and non-smokers.
Journal ArticleDOI
Effects of smoking on fluphenazine clearance in psychiatric inpatients
Larry Ereshefsky,Larry Ereshefsky,Michael W. Jann,Michael W. Jann,Stephen R. Saklad,Chester M. Davis,Ann L. Richards,Neil R. Burch +7 more
Journal ArticleDOI
Effects of carbamazepine on plasma haloperidol levels
M. W. Jann,Larry Ereshefsky,Stephen R. Saklad,Stephen R. Saklad,Donald Seidel,Chester M. Davis,Neil R. Burch,Charles L. Bowden +7 more
TL;DR: Monitoring of clinical symptoms and plasma haloperidol levels in schizophrenic patients when carbamazepine was either added or discontinued found no adverse effects during therapy.
Journal ArticleDOI
Clinical pharmacokinetics of the depot antipsychotics.
Michael W. Jann,Michael W. Jann,Larry Ereshefsky,Larry Ereshefsky,Stephen R. Saklad,Stephen R. Saklad +5 more
TL;DR: Withdrawal studies with fluphenazine decanoate suggest that relapsing patients have a more rapid plasma concentration decline than non-relapsed patients, and that the plasma concentrations do not decline smoothly but may exhibit ‘lumps’ due to residual release from previous injection sites or multicompartment redistribution.